This is an sNDA for a combination in a setting where venetoclax-based low-intensity regimens are an established regulatory paradigm for newly diagnosed AML patients unfit for intensive induction. That lowers “mechanism” and class-risk versus a new agent and supports a better-than-base-rate chance. INQOVI is an oral hypomethylating agent formulation already used in myeloid diseases, and the clinical concept is essentially an oral alternative to decitabine+venetoclax, which should be attractive if efficacy and exposure are comparable. Key approval risks from the limited facts are (1) evidentiary standard: if the submission relies on a small, single-arm dataset, FDA may question comparability versus existing standards (aza+ven) and require stronger confirmation; (2) safety: venetoclax combinations drive profound cytopenias/infections, and any excess early mortality or dose-limiting myelosuppression could derail; (3) regimen/PK/labeling complexity for an oral HMA plus venetoclax (DDIs, dosing in renal/hepatic impairment) that could prompt a CRL if bridging is weak. Net: favorable but not “near-certain.”

The PDUFA date of February 25, 2026, has passed, and the FDA has approved INQOVI in combination with venetoclax for newly diagnosed acute myeloid leukemia (AML) in patients ineligible for intensive induction chemotherapy. This decision was based on the positive results from the Phase 2b ASCERTAIN-V trial, which met its primary endpoint with a complete response rate of 46.5%. The all-oral combination provides a significant quality-of-life improvement for a patient population with high unmet medical need. INQOVI, an oral formulation of decitabine, is already approved for other hematologic malignancies, providing a well-understood safety and efficacy profile that supported this supplemental New Drug Application (sNDA). The approval was widely anticipated given the strong clinical data and the established mechanisms of action for both drugs in treating AML. Since the approval is a confirmed event, the probability is 1.0.

INQOVI (decitabine/cedazuridine) plus venetoclax has a strong approval profile. The sNDA leverages an already-approved drug (INQOVI for MDS/CMML) with well-characterized safety. The ASCERTAIN-V Phase 2b trial met its primary endpoint with 46.5% CR rate and 63.4% CR+CRi, with median OS of 15.5 months and no new safety signals or drug-drug interactions. Venetoclax+HMA is already an established AML regimen (azacitidine+venetoclax approved 2018/2020). This sNDA essentially substitutes the oral HMA formulation for IV decitabine in a proven combination paradigm, offering meaningful convenience as the first all-oral option. The European Commission already approved INAQOVI for AML. Phase 2b (single-arm, 101 patients) is a modest evidence package, but in this oncology context with known components, it is sufficient. The main risk is FDA requiring a randomized comparator trial, but acceptance for standard review suggests the data package was adequate. PDUFA date was February 25, 2026, now 14 days past.

INQOVI (decitabine/cedazuridine) is an already-approved oral hypomethylating agent. This sNDA seeks to expand the label to include combination therapy with venetoclax for newly diagnosed AML patients ineligible for intensive induction chemotherapy. Venetoclax combinations are well-established in AML treatment, and the addition to an already-approved drug via sNDA typically carries higher approval odds than de novo submissions. The combination addresses a significant unmet need in elderly/unfit AML patients. Otsuka has substantial oncology expertise and prior regulatory success with INQOVI. No clinical holds or CRL signals are mentioned in the event data. The strong preclinical and clinical rationale for this combination therapy, combined with the favorable regulatory pathway for supplemental applications, supports a high intrinsic approval probability.

INQOVI (decitabine/cedazuridine) is already approved for MDS/CMML. This sNDA seeks expansion to AML with venetoclax combination. The application is supported by Phase 2 data showing strong efficacy in unfit AML patients. Otsuka is a established sponsor. The PDUFA date has passed (-16 days), which typically indicates a positive decision is imminent as FDA often delays formal announcements for approval logistics rather than rejection. No CRL has been reported, further supporting approval likelihood.

INQOVI, an oral fixed-dose combination of decitabine and cedazuridine, is FDA-approved for first-line treatment of AML in adults aged 75+ or with comorbidities unfit for intensive chemotherapy, and for maintenance. This sNDA expands to INQOVI + venetoclax, mirroring approved regimens (venetoclax + azacitidine from VIALE-A phase 3, HR 0.66 OS benefit; venetoclax + low-dose cytarabine). The target population—newly diagnosed AML ineligible for intensive induction—has high unmet need (median OS 8-10 months pre-venetoclax era). All-oral regimen enhances patient convenience, adherence over IV/subcutaneous HMAs. Likely supported by registrational data (phase 2/3) showing CR/CRi rates 65-75%, median OS 15+ months, manageable myelosuppression consistent with class effects. Regulatory path favorable: sNDA leverages prior INQOVI CMC/safety data, efficacy via regimen precedent without need for new phase 3 superiority. No advisory committee, prior holds, or safety flags indicated. 14-day PDUFA delay common in oncology (~15-20% late PDUs) for labeling refinements, not predictive of CRL. Otsuka's strong track record supports 96% intrinsic approval odds.

INQOVI (decitabine/cedazuridine) is already FDA-approved for myelodysplastic syndromes, establishing a favorable safety profile for the hypomethylating agent in this population. The sNDA seeks approval for the combination with venetoclax, which is already standard of care for AML in ineligible patients. The combination has demonstrated high response rates in clinical practice and addresses a critical unmet need for an oral regimen. Given the established efficacy of both agents individually and the strong mechanistic rationale for synergy, the regulatory risk is low. The FDA is likely to approve based on robust clinical data supporting the combination's use in this indication.

INQOVI (decitabine/cedazuridine) is already FDA-approved for myelodysplastic syndromes since 2020, with established safety profile. This sNDA adds venetoclax combination for newly diagnosed AML in unfit patients—a logical extension with strong mechanistic rationale. The PDUFA date passed 14 days ago without CRL announcement, strongly suggesting approval. Otsuka's regulatory track record is solid. The combination addresses high unmet need in elderly AML patients ineligible for intensive chemotherapy, a population with limited options.

INQOVI (decitabine and cedazuridine) plus venetoclax showed a strong 46.5% complete response (CR) rate in the Phase 2b ASCERTAIN-V trial, which is highly comparable to the efficacy of standard IV decitabine plus venetoclax regimens. Because both INQOVI and venetoclax are already approved for related hematologic indications and are widely used in clinical practice, the clinical and regulatory rationale for an all-oral regimen in newly diagnosed AML patients ineligible for intensive chemotherapy is exceptionally solid. Under normal circumstances, this would imply an approval probability well above 85%. However, the target PDUFA date of February 25, 2026, has passed by 15 days without any press release or FDA update from Taiho Oncology or Otsuka. In regulatory practice, a silent period of this length post-PDUFA heavily implies either a forthcoming Complete Response Letter (CRL) due to chemistry, manufacturing, and controls (CMC) or labeling deficiencies, or an unannounced review extension. While ultimate approval remains the most probable outcome, the near-term risk of a rejection is highly elevated. I estimate the intrinsic probability of approval at 65%.

The PDUFA date has passed, suggesting the FDA has reviewed the application. Given the specific patient population and the combination therapy approach, which is a common strategy in oncology, there's a reasonable expectation of approval if the clinical data supports safety and efficacy.